Cargando…

Use of Intralesional Deoxycholic Acid for Antiretroviral Treatment Associated Lipohypertrophy: A Qualitative Open-Label Study of an Innovative Indication

BACKGROUND: With the advent of antiretroviral treatment (ART), human immunodeficiency virus/AIDS has become a chronic manageable disease. Though life expectancy has improved, it brings alongside effects of long-term medical treatment. One of the major side effects is body dysmorphism, which leads to...

Descripción completa

Detalles Bibliográficos
Autores principales: Kulkarni, Vinay, Salunke, Tejaswini S, Mandhane, Ambarish G, Vaidya, Pradyumna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405548/
https://www.ncbi.nlm.nih.gov/pubmed/37554685
http://dx.doi.org/10.4103/JCAS.JCAS_150_22
_version_ 1785085556536901632
author Kulkarni, Vinay
Salunke, Tejaswini S
Mandhane, Ambarish G
Vaidya, Pradyumna
author_facet Kulkarni, Vinay
Salunke, Tejaswini S
Mandhane, Ambarish G
Vaidya, Pradyumna
author_sort Kulkarni, Vinay
collection PubMed
description BACKGROUND: With the advent of antiretroviral treatment (ART), human immunodeficiency virus/AIDS has become a chronic manageable disease. Though life expectancy has improved, it brings alongside effects of long-term medical treatment. One of the major side effects is body dysmorphism, which leads to esthetic problems. Problems of lipodystrophy (LDS), especially facial lipoatrophy as well as facial and upper back lipohypertrophy are perceived by patients as highly stigmatizing manifestations of their human immunodeficiency virus infection. It has been reported to affect mood and quality of life, as well as reduced adherence to antiretroviral medications. Patients feel discomfort while sleeping, dressing, and during day-to-day activities. AIM: The aim of this study was to test a relatively cost-effective and efficacious treatment modality for long-standing ART-associated lipohypertrophy of the submental fat and dorsocervical fat. MATERIALS AND METHODS: This was a prospective open-label clinical study, in which 21 patients on regular ART with associated lipohypertrophy were enrolled in this open-label study. Deoxycholic acid (DCA) was given intralesionally once every 4–6 weeks. Patients were assessed for response, any adverse events, and patient satisfaction during every visit. RESULTS: Intralesional DCA seems to be a promising treatment modality for long-standing ART-induced LDS with better cost-benefit in comparison with surgical interventions. LIMITATIONS: It was a small-sized sample that was studied. The lag time between starting the treatment and optimum results was long in comparison with liposuction. The result is better appreciated at the end of treatment rather than after every session implying that it has a cumulative effect. Neither pre- and post-ultrasonography nor metric documentation was done. CONCLUSIONS: Intralesional DCA seems to be a promising treatment modality for long-standing ART-induced LDS with better cost–benefit in comparison with surgical interventions.
format Online
Article
Text
id pubmed-10405548
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-104055482023-08-08 Use of Intralesional Deoxycholic Acid for Antiretroviral Treatment Associated Lipohypertrophy: A Qualitative Open-Label Study of an Innovative Indication Kulkarni, Vinay Salunke, Tejaswini S Mandhane, Ambarish G Vaidya, Pradyumna J Cutan Aesthet Surg Original Article BACKGROUND: With the advent of antiretroviral treatment (ART), human immunodeficiency virus/AIDS has become a chronic manageable disease. Though life expectancy has improved, it brings alongside effects of long-term medical treatment. One of the major side effects is body dysmorphism, which leads to esthetic problems. Problems of lipodystrophy (LDS), especially facial lipoatrophy as well as facial and upper back lipohypertrophy are perceived by patients as highly stigmatizing manifestations of their human immunodeficiency virus infection. It has been reported to affect mood and quality of life, as well as reduced adherence to antiretroviral medications. Patients feel discomfort while sleeping, dressing, and during day-to-day activities. AIM: The aim of this study was to test a relatively cost-effective and efficacious treatment modality for long-standing ART-associated lipohypertrophy of the submental fat and dorsocervical fat. MATERIALS AND METHODS: This was a prospective open-label clinical study, in which 21 patients on regular ART with associated lipohypertrophy were enrolled in this open-label study. Deoxycholic acid (DCA) was given intralesionally once every 4–6 weeks. Patients were assessed for response, any adverse events, and patient satisfaction during every visit. RESULTS: Intralesional DCA seems to be a promising treatment modality for long-standing ART-induced LDS with better cost-benefit in comparison with surgical interventions. LIMITATIONS: It was a small-sized sample that was studied. The lag time between starting the treatment and optimum results was long in comparison with liposuction. The result is better appreciated at the end of treatment rather than after every session implying that it has a cumulative effect. Neither pre- and post-ultrasonography nor metric documentation was done. CONCLUSIONS: Intralesional DCA seems to be a promising treatment modality for long-standing ART-induced LDS with better cost–benefit in comparison with surgical interventions. Wolters Kluwer - Medknow 2023 /pmc/articles/PMC10405548/ /pubmed/37554685 http://dx.doi.org/10.4103/JCAS.JCAS_150_22 Text en Copyright: © 2023 Journal of Cutaneous and Aesthetic Surgery https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Kulkarni, Vinay
Salunke, Tejaswini S
Mandhane, Ambarish G
Vaidya, Pradyumna
Use of Intralesional Deoxycholic Acid for Antiretroviral Treatment Associated Lipohypertrophy: A Qualitative Open-Label Study of an Innovative Indication
title Use of Intralesional Deoxycholic Acid for Antiretroviral Treatment Associated Lipohypertrophy: A Qualitative Open-Label Study of an Innovative Indication
title_full Use of Intralesional Deoxycholic Acid for Antiretroviral Treatment Associated Lipohypertrophy: A Qualitative Open-Label Study of an Innovative Indication
title_fullStr Use of Intralesional Deoxycholic Acid for Antiretroviral Treatment Associated Lipohypertrophy: A Qualitative Open-Label Study of an Innovative Indication
title_full_unstemmed Use of Intralesional Deoxycholic Acid for Antiretroviral Treatment Associated Lipohypertrophy: A Qualitative Open-Label Study of an Innovative Indication
title_short Use of Intralesional Deoxycholic Acid for Antiretroviral Treatment Associated Lipohypertrophy: A Qualitative Open-Label Study of an Innovative Indication
title_sort use of intralesional deoxycholic acid for antiretroviral treatment associated lipohypertrophy: a qualitative open-label study of an innovative indication
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405548/
https://www.ncbi.nlm.nih.gov/pubmed/37554685
http://dx.doi.org/10.4103/JCAS.JCAS_150_22
work_keys_str_mv AT kulkarnivinay useofintralesionaldeoxycholicacidforantiretroviraltreatmentassociatedlipohypertrophyaqualitativeopenlabelstudyofaninnovativeindication
AT salunketejaswinis useofintralesionaldeoxycholicacidforantiretroviraltreatmentassociatedlipohypertrophyaqualitativeopenlabelstudyofaninnovativeindication
AT mandhaneambarishg useofintralesionaldeoxycholicacidforantiretroviraltreatmentassociatedlipohypertrophyaqualitativeopenlabelstudyofaninnovativeindication
AT vaidyapradyumna useofintralesionaldeoxycholicacidforantiretroviraltreatmentassociatedlipohypertrophyaqualitativeopenlabelstudyofaninnovativeindication